title: Characterization of sulfonylurea receptors and the action of potassium channel openers on cholinergic neurotransmission in guinea pig isolated small intestine.
abstract: Specific binding sites for [3H]glibenclamide, a potent ATP-sensitive K+ channel blocker, have been characterized in the isolated guinea pig longitudinal muscle-myenteric plexus preparation. The Scatchard plot of the saturation isotherm was curvilinear and revealed two binding sites, one of high affinity (Kd = 0.42 nM; maximum binding site = 156 fmol/mg of protein), the other of low affinity (Kd = 83 nM; maximum binding site = 3100 fmol/mg of protein). Displacement experiments in the presence of various sulfonylureas showed the same order of potency for the two binding sites (glibenclamide greater than gliquidone greater than glipizide glibornuride greater than chlorpropamide greater than tolbutamide). The K+ channel opener RP 49356 (but not diazoxide or cromakalim) displaced the [3H] glibenclamide with an IC50 of 4.8 microM. The effects of the K+ channel openers diazoxide, RP 49356, cromakalim and its two optical isomers BRL 38226 and BRL 38227 were also studied on the electrically induced contractions of isolated guinea pig small intestine. These compounds produce an inhibition of neurally evoked twitch height with pD2 values of 4.5 to 6.2 (BRL 38227 greater than cromakalim greater than RP 49356 greater than diazoxide, whereas BRL 38226 was practically ineffective). The effects of cromakalim and RP 49356 were antagonized competitively by glibenclamide (pA2 = 7.2) and other sulfonylureas, suggesting they act on ATP-sensitive K+ channels. Affinities of the sulfonylureas obtained from concentration-response curves to cromakalim on electrically induced contractions are better correlated with the IC50 value corresponding to the low affinity binding site than to the high affinity.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Laboratoire de Neurobiologie et Physiopathologie du Developement, Institut National de la Santé et de la Recherche Médicale U29, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Zini
authors.forename: Y
authors.initials: Y
authors.lastname: Ben-Ari
authors.forename: M L
authors.initials: ML
authors.lastname: Ashford
mesh_terms: D018528:ATP-Binding Cassette Transporters; D000255:Adenosine Triphosphate / Q000502:physiology*; D000818:Animals; D001578:Benzopyrans / Q000037:antagonists & inhibitors / Q000378:metabolism; D002794:Choline / Q000502:physiology*; D019806:Cromakalim; D004558:Electric Stimulation; D005905:Glyburide / Q000378:metabolism; D006168:Guinea Pigs; D007421:Intestine, Small / Q000187:drug effects / Q000294:innervation* / Q000378:metabolism; D007700:Kinetics; D008297:Male; D009119:Muscle Contraction / Q000502:physiology; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation / Q000378:metabolism; D009197:Myenteric Plexus / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D010847:Picolines / Q000037:antagonists & inhibitors / Q000378:metabolism; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D024661:Potassium Channels, Inwardly Rectifying; D011714:Pyrans / Q000037:antagonists & inhibitors / Q000378:metabolism; D011758:Pyrroles / Q000037:antagonists & inhibitors / Q000378:metabolism; D011955:Receptors, Drug / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D064233:Sulfonylurea Receptors; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*; D014316:Tritium
chemical_list: D018528:ATP-Binding Cassette Transporters; D001578:Benzopyrans; D010847:Picolines; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D011714:Pyrans; D011758:Pyrroles; D011955:Receptors, Drug; D064233:Sulfonylurea Receptors; D019806:Cromakalim; D014316:Tritium; C061043:aprikalim; D000255:Adenosine Triphosphate; D002794:Choline; D005905:Glyburide